Table 3 Univariate and multivariate analysis of CSS in the patients with chemotherapy and without chemotherapy.

From: Association between chemotherapy and prognostic factors of survival in hepatocellular carcinoma: a SEER population-based cohort study

Variables

Non-chemotherapy(n = 503)

Chemotherapy(n = 509)

 

Univariate analysis

Multivariate analysis

 

Univariate analysis

Multivariate analysis

N

P value

HR(95%CI)

P value

N

P value

HR(95%CI)

P value

Sex

        

 Female

106

 

Reference

 

110

 

Reference

 

 Male

397

0.0904

0.757 (0.528–1.086)

0.131

399

0.098

0.094 (0.709–1.310)

0.814

Age at diagnosis

        

  < 59 years

237

 

Reference

 

231

 

Reference

 

 59–66 years

160

0.9301

1.294 (0.935–1.791)

0.121

160

0.1412

1.154 (0.855–1.557)

0.351

 66–74 years

106

0.0441*

1.083 (0.775–1.515)

0.640

118

0.0198*

1.108 (0.791–1.553)

0.550

Race

        

 White

338

 

—

 

342

 

—

 

 Black

70

0.943

—

—

70

0.371

—

—

 Others

95

0.992

—

—

97

0.596

—

—

AJCC

        

 I

191

 

Reference

 

202

 

Reference

 

 II

188

0.255

1.995 (1.383–2.876)

 < 0.001*

173

0.598

1.506 (1.066–2.126)

0.020*

 III

79

 < 0.001***

2.623 (1.752–3.929)

 < 0.001*

91

 < 0.001***

1.968 (1.346–2.878)

 < 0.001***

 IV

45

 < 0.001***

3.791 (2.452–5.859)

 < 0.001*

43

 < 0.001***

2.589 (1.630–3.777)

 < 0.001***

Tumor size

        

  < 3.5 cm

228

 

Reference

 

232

 

Reference

 

 3.5–7.2 cm

176

 < 0.001***

1.663 (1.165–2.373)

0.005**

168

 < 0.001***

1.574 (1.121–2.210)

0.009**

  > 7.2 cm

99

 < 0.001***

2.274 (1.470–3.516)

 < 0.001*

109

 < 0.001***

2.481 (1.630–3.777)

 < 0.001***

AFP

        

 Negative

141

 

Reference

 

160

 

Reference

 

 Positive

362

0.0524

1.173 (0.854–1.613)

0.325

349

0.0433*

1.487 (1.095–2.020)

0.011*

Fibrosis score

        

 F0

122

 

—

 

119

 

Reference

 

 F1

381

0.49

—

—

390

0.0252*

1.105 (0.796–1.534)

0.550

Grade, n (%)

        

 Well differentiated

156

 

Reference

 

163

 

Reference

 

 Moderately differentiated

250

0.0487*

1.522 (1.095–2.117)

0.013*

256

0.76322

1.241 (0.908–1.696)

0.176

 Poorly differentiated

93

 < 0.001***

2.097 (1.412–3.114)

 < 0.001***

85

0.00244**

1.616 (1.104–2.365)

0.014*

 Undifferentiated

4

0.3476

2.911 (0.656–12.913)

0.160

5

0.18377

1.792 (0.618–5.195)

0.282

Surgery

        

 No surgery

203

 

Reference

 

202

 

Reference

 

 Hepatectomy

101

 < 0.001***

0.124 (0.078–0.198)

 < 0.001***

103

 < 0.001***

0.357 (0.248–0.513)

 < 0.001***

 Hepatectomy and transplant

139

 < 0.001***

0.074 (0.042–0.132)

 < 0.001***

137

 < 0.001***

0.111 (0.064–0.192)

 < 0.001***

 Others

60

 < 0.001***

0.393 (0.249–0.620)

 < 0.001***

67

 < 0.001***

0.689 (0.474–1.001)

0.051

Radiotherapy

        

 No

458

 

Reference

 

465

 

Reference

 

 Yes

45

 < 0.001***

0.519 (0.341–0.789)

0.002**

44

 < 0.001***

1.182 (0.781–1.789)

0.429

  1. *Two-sided P values < 0.05.
  2. **Two-sided P values < 0.01.
  3. ***Two-sided P values < 0.001.
  4. CSS, cancer-specific survival; HR, hazard ratio; CI, coindidence intervals; AJCC, American Joint Committee on Cancer (7th).
  5. F0, fibrosis score 0–4, non to moderate fibrosis; F1, fibrosis score 5–6, severe fibrosis and cirrhosis.
Back to article page